封面
市场调查报告书
商品编码
1602808

抗肥胖处方药市场:按药物类别、年龄层、分销管道划分 - 全球预测 2025-2030

Anti-obesity Prescription Drugs Market by Drug Class (Bupropion & Naltrexone, Liraglutide, Lorcaserin), Age Group (Adult, Pediatric), Distribution Channel - Global Forecast 2025-2030

出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗肥胖处方药市值为62.2亿美元,预计2024年将达到67.1亿美元,复合年增长率为8.12%,预计到2030年将达到107.4亿美元。

处方抗肥胖药物是专门设计的药物,旨在透过改变代谢或食慾调节途径来帮助减肥。这些药物的需求源于全球肥胖流行,肥胖与糖尿病、心血管疾病和某些癌症等严重的健康併发症有关。这些药物主要针对身体质量指数 (BMI) 为 30 或更高或出现肥胖相关症状的人。主要最终用户包括医疗机构、诊所和药房,健康中心和远端医疗平台的兴趣日益浓厚。

主要市场统计
基准年[2023] 62.2亿美元
预测年份 [2024] 67.1亿美元
预测年份 [2030] 107.4亿美元
复合年增长率(%) 8.12%

抗肥胖药物市场受到肥胖率上升以及人们对肥胖相关健康风险的认识不断增强的影响,从而刺激了对有效治疗方案的需求。药物配方和给药方面的技术进步,加上政府的支持措施和研究经费,将进一步刺激市场成长。机会包括扩展到肥胖率上升且医疗需求未满足的新兴市场。製药公司和数位健康新兴企业之间的合作提供全面的体重管理解决方案也是一个有前途的途径。然而,高昂的研发成本、严格的监管核准以及与长期用药相关的潜在副作用给市场成长带来了挑战。

创新对于应对这些挑战至关重要,有前景的领域包括开发针对基因谱的个人化医疗以及人工智慧和巨量资料的整合,以提高药物疗效和患者依从性。此外,探索利用多种机制来增强减重效果的联合治疗可以让您在市场上脱颖而出。总体而言,抗肥胖药物市场的性质是动态的,并且随着趋势转向整体医疗保健解决方案,具有巨大的成长潜力。投资稳健的临床试验并考虑多样化市场需求的公司更有可能取得成功,从而最大限度地提高公共卫生效益和经济回报。

市场动态:揭示快速发展的抗肥胖处方药市场的关键市场洞察

抗肥胖处方药市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态,公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险,同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 肥胖及相关慢性病盛行率上升
    • 不健康和久坐的生活方式增加
    • 製药公司、医科大学/研究机构和政府机构的医学研究进展
  • 市场限制因素
    • 抗肥胖药物的副作用
  • 市场机会
    • 新型抗肥胖药物介绍
    • 肥胖管理意识不断增强
  • 市场挑战
    • 替代治疗方案的可用性

波特五力:驾驭抗肥胖处方药市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势,解决弱点并避免潜在的挑战,从而确保更强大的市场地位。

PESTLE分析:了解抗肥胖处方药市场的外部影响

外部宏观环境因素在塑造抗肥胖处方药市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素,公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化,并为他们做出积极主动的决策做好准备。

市场占有率分析 了解抗肥胖处方药市场的竞争格局

抗肥胖处方药市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势,为供应商提供了製定策略决策所需的见解,以应对日益激烈的竞争。

FPNV 定位矩阵抗肥胖处方药市场供应商的绩效评估

FPNV定位矩阵是评估抗肥胖处方药市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商,从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商,并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议,规划抗肥胖处方药市场的成功之路

对于旨在加强在全球市场的影响力的公司来说,抗肥胖处方药市场的策略分析至关重要。透过审查关键资源、能力和绩效指标,公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战,利用新的商机,并取得长期成功。

本报告对市场进行了全面分析,涵盖关键重点领域:

1. 市场渗透率:对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓:辨识新兴市场的成长机会,评估现有领域的扩张潜力,并提供未来成长的策略蓝图。

3. 市场多元化:分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报:彻底分析竞争格局,检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新:重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题,以帮助相关人员做出明智的决策:

1.目前的市场规模和未来的成长预测是多少?

2. 哪些产品、区隔市场和地区提供最佳投资机会?

3.塑造市场的主要技术趋势和监管影响是什么?

4.主要厂商的市场占有率和竞争地位如何?

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么?

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 肥胖和相关慢性疾病的增加
      • 不健康和久坐的生活方式增加
      • 促进製药公司、医科大学/研究机构和政府机构的医学研究
    • 抑制因素
      • 与抗肥胖药物相关的副作用
    • 机会
      • 新型抗肥胖药物介绍
      • 提高肥胖管理意识
    • 任务
      • 替代治疗方案的可用性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别分類的抗肥胖处方药市场

  • 安非他酮和纳曲酮
  • Liraglutide
  • 氯卡色林
  • 奥利司他
  • 芬特明和托吡酯

第七章抗肥胖处方药市场:依年龄组

  • 成人用
  • 小儿科

第八章抗肥胖处方药市场:依通路

  • 医院药房
  • 网路药房
  • 零售药房

第九章美洲抗肥胖处方药市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太抗肥胖处方药市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲抗肥胖处方药市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵,2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Alisier Drugs Pvt. Ltd.
  • Arena Pharmaceuticals Ltd
  • Arrowhead Pharmaceuticals, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Currax Pharmaceuticals LLC
  • Eisai Co., Ltd
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Norgine BV
  • Novo Nordisk A/s
  • SHIONOGI & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • VIVUS LLC
  • Zydus Lifesciences Limited
Product Code: MRR-4358BACA7FD1

The Anti-obesity Prescription Drugs Market was valued at USD 6.22 billion in 2023, expected to reach USD 6.71 billion in 2024, and is projected to grow at a CAGR of 8.12%, to USD 10.74 billion by 2030.

Anti-obesity prescription drugs are specialized pharmaceuticals designed to aid in weight loss by altering metabolic or appetite-regulating pathways. The necessity for these medications arises from the global obesity epidemic, which is associated with severe health complications such as diabetes, cardiovascular diseases, and certain cancers. Their application predominantly targets individuals with a body mass index (BMI) of 30 or higher, or those experiencing obesity-related conditions. The predominant end-users include healthcare facilities, clinics, and pharmacies, with a growing interest from wellness centers and telemedicine platforms.

KEY MARKET STATISTICS
Base Year [2023] USD 6.22 billion
Estimated Year [2024] USD 6.71 billion
Forecast Year [2030] USD 10.74 billion
CAGR (%) 8.12%

The market for anti-obesity drugs is influenced by a rise in obesity rates and increasing awareness of the health risks associated with obesity, fueling demand for effective treatment options. Technological advancements in drug formulation and delivery, along with government supportive initiatives and research funding, further stimulate market growth. Opportunities lie in expanding into emerging markets where obesity rates are climbing, and there are unmet medical needs. Collaborative efforts between pharmaceutical companies and digital health startups to provide comprehensive weight management solutions represent another promising avenue. Yet, market growth is challenged by high R&D costs, stringent regulatory approvals, and potential side effects associated with long-term drug use, which can result in patient reluctance and limited adherence.

Innovation is pivotal in addressing these challenges, with potential areas including the development of personalized medicine tailored to genetic profiles and the integration of AI and big data to enhance drug efficacy and patient compliance. Additionally, exploring combination therapies that utilize multiple mechanisms to enhance weight loss outcomes can differentiate market offerings. Overall, the nature of the anti-obesity drug market is dynamic, with vast potential for growth as trends shift towards holistic healthcare solutions. Businesses that invest in robust clinical trials and consider diverse market needs are likely to thrive, maximizing both public health benefits and economic returns.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-obesity Prescription Drugs Market

The Anti-obesity Prescription Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of obesity and related chronic diseases
    • Growing unhealthy and sedentary lifestyle
    • Advancement in medical research by drug-manufacturing companies, medical universities and institutes, and government agencies
  • Market Restraints
    • Side effect related to anti-obesity drugs
  • Market Opportunities
    • Introduction of novel anti-obesity drugs
    • Accelerating awareness towards obesity management
  • Market Challenges
    • Availability of alternative treatment options

Porter's Five Forces: A Strategic Tool for Navigating the Anti-obesity Prescription Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-obesity Prescription Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-obesity Prescription Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-obesity Prescription Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-obesity Prescription Drugs Market

A detailed market share analysis in the Anti-obesity Prescription Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-obesity Prescription Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-obesity Prescription Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-obesity Prescription Drugs Market

A strategic analysis of the Anti-obesity Prescription Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-obesity Prescription Drugs Market, highlighting leading vendors and their innovative profiles. These include Alisier Drugs Pvt. Ltd., Arena Pharmaceuticals Ltd, Arrowhead Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co., Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Norgine BV, Novo Nordisk A/s, SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, VIVUS LLC, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Anti-obesity Prescription Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Bupropion & Naltrexone, Liraglutide, Lorcaserin, Orlistat, and Phentermine & Topiramate.
  • Based on Age Group, market is studied across Adult and Pediatric.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of obesity and related chronic diseases
      • 5.1.1.2. Growing unhealthy and sedentary lifestyle
      • 5.1.1.3. Advancement in medical research by drug-manufacturing companies, medical universities and institutes, and government agencies
    • 5.1.2. Restraints
      • 5.1.2.1. Side effect related to anti-obesity drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of novel anti-obesity drugs
      • 5.1.3.2. Accelerating awareness towards obesity management
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative treatment options
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-obesity Prescription Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Bupropion & Naltrexone
  • 6.3. Liraglutide
  • 6.4. Lorcaserin
  • 6.5. Orlistat
  • 6.6. Phentermine & Topiramate

7. Anti-obesity Prescription Drugs Market, by Age Group

  • 7.1. Introduction
  • 7.2. Adult
  • 7.3. Pediatric

8. Anti-obesity Prescription Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Americas Anti-obesity Prescription Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Anti-obesity Prescription Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Anti-obesity Prescription Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alisier Drugs Pvt. Ltd.
  • 2. Arena Pharmaceuticals Ltd
  • 3. Arrowhead Pharmaceuticals, Inc.
  • 4. Boehringer Ingelheim International GmbH
  • 5. Bristol-Myers Squibb Company
  • 6. Currax Pharmaceuticals LLC
  • 7. Eisai Co., Ltd
  • 8. F. Hoffmann-La Roche AG
  • 9. GlaxoSmithKline PLC
  • 10. Norgine BV
  • 11. Novo Nordisk A/s
  • 12. SHIONOGI & Co., Ltd.
  • 13. Takeda Pharmaceutical Company Limited
  • 14. VIVUS LLC
  • 15. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. ANTI-OBESITY PRESCRIPTION DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-OBESITY PRESCRIPTION DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY BUPROPION & NALTREXONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LORCASERIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PHENTERMINE & TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. ANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2023